Cargando…
Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes
Sodium glucose transporter type 2 (SGLT2) molecules are found in proximal tubules of the kidney, and perhaps in the brain or intestine, but rarely in any other tissue. However, their inhibitors, intended to improve diabetes compensation, have many more beneficial effects. They improve kidney and car...
Autores principales: | Čertíková Chábová, Věra, Zakiyanov, Oskar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911473/ https://www.ncbi.nlm.nih.gov/pubmed/35269954 http://dx.doi.org/10.3390/ijms23052812 |
Ejemplares similares
-
Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019) -
Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022) -
Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal
por: Gupta, Vishal, et al.
Publicado: (2017) -
The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
por: Patel, Dhiren K., et al.
Publicado: (2019) -
Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering
por: Yanai, Hidekatsu, et al.
Publicado: (2016)